New publication using Mesentech drug-candidates: In Vivo Bone Effects of a Novel Bisphosphonate‐EP4a Conjugate Drug (C3) for Reversing Osteoporotic Bone Loss in an Ovariectomized Rat Model.
Treatment with MES-1007 significantly increased trabecular bone volume and vertebral bone mineral density versus controls. There was also significant improvement in the vertebral load bearing abilities and stimulation of bone formation in femurs after MES-1007. This paper also proves that conjugation of EP4 and the bone-targeting linker is vital to anabolic efficacy.